Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis

Open access
Langford, Carol A., Cuthbertson, David, Ytterberg, Steven R., Khalidi, Nader, Monach, Paul A., Carette, Simon, Seo, Philip, Moreland, Larry W., Weisman, Michael, Koening, Curry L., Sreih, Antoine G., Spiera, Robert, McAlear, Carol A., Warrington, Kenneth J., Pagnoux, Christian, McKinnon, Kathleen, Forbess, Lindsy J., Hoffman, Gary S., Borchin, Renée, Krischer, Jeffrey P., Merkel, Peter A., for the Vasculitis Clinical Research Consortium·2017·Arthritis & Rheumatology

Abstract

Objective: To compare the efficacy of abatacept to that of placebo for the treatment of Takayasu arteritis (TAK). Methods: In this multicenter trial, patients with newly diagnosed or relapsing TAK were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double‐blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, reaching a dosage of 20 mg daily at week 12, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse‐free survival). Results: Thirty‐four eligible patients with TAK were enrolled and treated with prednisone and abatacept; of these, 26 reached the week 12 randomization and underwent a blinded randomization to receive either abatacept or placebo. The relapse‐free survival rate at 12 months was 22% for those receiving abatacept and 40% for those receiving placebo (P = 0.853). Treatment with abatacept in patients with TAK enrolled in this study was not associated with a longer median duration of remission (median duration 5.5 months for abatacept versus 5.7 months for placebo). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms. Conclusion: In patients with TAK, the addition of abatacept to a treatment regimen with prednisone did not reduce the risk of relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.40037

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 167

Metadata

Authors
Langford, C. A., Cuthbertson, D., Ytterberg, S. R., Khalidi, N., Monach, P. A., Carette, S., Seo, P., Moreland, L. W., Weisman, M., Koening, C. L., Sreih, A. G., Spiera, R., McAlear, C. A., Warrington, K. J., Pagnoux, C., McKinnon, K., Forbess, L. J., Hoffman, G. S., Borchin, R., Krischer, J. P., Merkel, P. A., & for the Vasculitis Clinical Research Consortium
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2017-03-08
Volume
69
Issue
4
Pages
846-853
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W4236596248
Cited by
167
References
1
FWCI
14.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis. https://app.cochat.ai/papers/10.1002/art.40037
The paper
Langford, C. A., Cuthbertson, D., Ytterberg, S. R., Khalidi, N., Monach, P. A., Carette, S., Seo, P., Moreland, L. W., Weisman, M., Koening, C. L., Sreih, A. G., Spiera, R., McAlear, C. A., Warrington, K. J., Pagnoux, C., McKinnon, K., Forbess, L. J., Hoffman, G. S., Borchin, R., . . . for the Vasculitis Clinical Research Consortium. (2017). A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.40037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.